These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6359729)

  • 1. Bone marrow transplantation as immunotherapy.
    Sondel PM
    Wis Med J; 1983 Oct; 82(10):17-9. PubMed ID: 6359729
    [No Abstract]   [Full Text] [Related]  

  • 2. Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.
    Ringdén O; Deeg HJ; Beschorner W; Slavin S
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2758-61. PubMed ID: 3547953
    [No Abstract]   [Full Text] [Related]  

  • 3. Manipulation of T-cell content in transplanted human bone marrow: effect on GVH and GVL reactions.
    Truitt RL; Ash RC
    Prog Clin Biol Res; 1987; 244():409-21. PubMed ID: 3310003
    [No Abstract]   [Full Text] [Related]  

  • 4. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenophobia, T cells and a journey to a foreign land.
    Gale RP; Butturini A
    Thymus; 1990 Aug; 16(1):1-5. PubMed ID: 2219230
    [No Abstract]   [Full Text] [Related]  

  • 7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
    Gajewski J; Gjertson D; Cecka M; Tonai R; Przepiorka D; Hunt L; Giralt S; Chan KW; Feig S; Territo M; Andersson B; van Besien K; Khouri I; Fischer H; Babbitt L; Ippolitti C; Schiller G; Lill M; Warkentin D; Neumann J; Petz L; Terasaki P; Champlin R
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):76-82. PubMed ID: 9267667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulation of T cells in the transplant inoculum.
    Kersey J
    Int J Cell Cloning; 1986; 4 Suppl 1():122-6. PubMed ID: 3528329
    [No Abstract]   [Full Text] [Related]  

  • 12. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of immunotherapy in bone marrow transplantation for acute myeloid leukemia.
    Prentice HG; Macdonald ID; Hamon MD
    Prog Clin Biol Res; 1994; 389():239-43. PubMed ID: 7700907
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of minimal residual disease in acute leukemia--focus on immunotherapeutic options.
    Simonsson B; Nilsson BI; Rowe JM
    Leukemia; 1992 Nov; 6 Suppl 4():124-34. PubMed ID: 1279326
    [No Abstract]   [Full Text] [Related]  

  • 16. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
    Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
    Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to enhance the graft-versus-malignancy effect in allogeneic transplants.
    Barrett JA
    Ann N Y Acad Sci; 1995 Dec; 770():203-12. PubMed ID: 8597361
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for leukemia.
    Butturini A; Gale RP
    Curr Opin Hematol; 1994 Nov; 1(6):402-5. PubMed ID: 9371313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Graft vs host disease].
    Moalic V; Ferec C
    Pathol Biol (Paris); 2006 May; 54(5):304-8. PubMed ID: 16530350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.